pillbase.ru

Harvoni

Active substance: LEDIPASVIR, SOFOSBUVIR

PELLET · LEDIPASVIR 33.75 mg/1, SOFOSBUVIR 150 mg/1

United StatesActive

Marketing holder: Gilead Sciences, Inc

Verified 2026-10-09 · openFDA NDC

Analogues in other countries
Composition
Products containing ledipasvir in other countries

Showing products with this active substance, combinations included; the full composition is shown for each product.

CountryProducts
RU 3
  • Гарвони®
    таблетки, покрытые пленочной оболочкой, 90 мг+400 мг (original in Russian, GRLS)
    ЛП-№(006349)-(РГ-RU)
    Гилеад Сайенсиз Интернешнл Лимитед
  • Гарвони®
    таблетки, покрытые пленочной оболочкой, 90 мг+400 мг (original in Russian, GRLS)
    ЛП-006104
    Гилеад Сайенсиз Интернешнл Лимитед
  • Ледипасоф
    таблетки, покрытые пленочной оболочкой, 90 мг+400 мг (original in Russian, GRLS)
    ЛП-№(006609)-(РГ-RU)
    Акционерное общество "Фармасинтез" (АО "Фармасинтез")
EU 1
  • Harvoni
    ledipasvir, sofosbuvir
    EMEA/H/C/003850
    Gilead Sciences Ireland UC
Registration
Registration number
61958-1805
Registration status
Active
Dispensing
Prescription only
Route
ORAL
Sources
  • product · openFDA NDC · 61958-1805 · Verified 2026-10-09 · open in source
  • registration_status · openFDA NDC · 61958-1805 · Verified 2026-10-09 · open in source
  • ingredients.0 · openFDA NDC · 61958-1805 · Verified 2026-10-09 · open in source
  • ingredients.1 · openFDA NDC · 61958-1805 · Verified 2026-10-09 · open in source